Extended Data Fig. 6: Efficacy and mechanism of action study of atezolizumab-bevacizumab in an immunogenic hepatocellular carcinoma mouse model.

a, Survival curves in C57BL/6 WT females. Number of mice per group is shown as well as median survival in days. Log-rank Mantel-Cox test. Treatment groups are compared with the control group (IgG1 + IgG2) and two-sided P value is adjusted. b-i, Quantification of (b) CD8 T cells, (c) proliferating CD8 T cells, (d) proliferating SIINFELKL-specific CD8 T cells, (e) granzyme B-expressing SIINFELKL-specific CD8 T cells, (f) proliferating Tregs, (g) ratio of proliferating Tregs, (h) conventional dendritic cells (cDCs), and (i) monocyte-derived macrophages (MoMa) in the livers of MYC-lucOS;CTNNB1 2 weeks after starting treatments (n = 5 biologically independent animals). Results of an analysis of variance test with multiple comparisons is shown. Mean and standard deviation (SD) are shown. j, Representative pictures of the stainings for CD8 (pink) and endomucin (brown) in tumor area quantified in (k). k & l, Number of CD8 + T cells and endomucin-positive vessels per mm² of (k) tumor and (l) peritumor areas in MYC-lucOS; CTNNB1 mice treated with the corresponding treatments for 2 weeks (n = 2-5 biologically independent animals). An analysis of variance test with multiple comparisons is shown. Mean and standard deviation (SD) are shown. C, control (IgG1 + IgG2), P, anti–PD-L1; PV, anti–PD-L1 + anti-VEGF; Undef, undefined; V, anti-VEGF.